Clinical trials: Dyslipidemias
Hypercholesterolemia, Coronary Heart Disease
Evaluation of the Efficacy of Rosuvastatin in Daily Practice (TARGET)
In this study the effect of the switch to rosuvastatin from another statin (fluvastatin, pravastatin, simvastatin, atorvastatin) was evaluated in high-risk patients with and without evident CHD and LDL-C ≥ 3.2 mmol/l.
- Trial name
- NCT00396110
- Volunteers
- 3,889 people
- Sponsor
- AstraZeneca
Cardiovascular Disease
An Open-label Single Dose Randomized, Parallel Group Study Followed by Single-blind Repeat Dosing, to Compare the Relative Bioavailability of GSK2212836.
Sixteen healthy subjects will be randomized to each of the 3 parallel treatment groups. Eligible subjects will check in to the clinical unit on Day -2 and have 24-hr pharmacokinetic collections on Day -1 and on Day 1.
- Trial name
- NCT00996268
- Testing
- GSK2212836
- Where
- United States
- Volunteers
- 46 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Hypercholesterolemia, Atherosclerosis
Effect of Ezetimibe Plus Simvastatin on Flow-Mediated Brachial Artery Vasoactivity in Subjects With Primary Hypercholesterolemia (Study P03336)
The purpose of this study is to evaluate the effect of ezetimibe coadministered with simvastatin compared with simvastatin alone when administered for 12 weeks on endothelial function as assessed by brachial artery reactivity…
- Trial name
- NCT00651391
- Testing
- Ezetimibe + Simvastatin, Simvastatin
- Volunteers
- 28 people
- Sponsor
- Organon and Co
Hypercholesterolemia
Real-life EValuation Of High Dose RosUvastatin in High Risk Patients After TitraTION
To evaluate achievement ratio of treatment target goal in hypercholesterolemia patients with high risk after high dose rosuvastatin(20mg/day) titration
- Trial name
- REVORUTION (NCT00526721)
- Where
- 3 sites in South Korea
- Volunteers
- 1,482 people
- Sponsor
- AstraZeneca
Hypercholesterolemia
Efficacy and Safety Study of Pitavastatin Versus Atorvastatin to Treat Hypercholesterolemia
Statin is an effective drug to treat hyperlipidemia (hypercholesterolemia), and it rarely leads to hepatic damage to the patients with hepatic disorder. For these patients, intensive monitoring is required.
- Trial name
- PITCH (NCT01166633)
- Testing
- pitavastatin, atorvastatin
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- JW Pharmaceutical
Dyslipidemia
To Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AZD8233 After Multiple Dose Administration in Subjects With Dyslipidemia
This is a Phase I study to assess the safety, tolerability and pharmacokinetics (PK), and pharmacodynamics (PD) of AZD8233, following subcutaneous (SC) administration of multiple ascending doses (MAD) of AZD8233 in subjects with…
- Trial name
- NCT04155645
- Testing
- AZD8233 subcutaneous injection
- Where
- 7 sites in United States
- Volunteers
- 34 people
- Sponsor
- AstraZeneca
Hyperlipidemia, Dyslipidemia
A Clinical Trial Comparing Torcetrapib/Atorvastatin To Simvastatin In Subjects With High Cholesterol (A5091031).
The Torcetrapib project was terminated on December 2, 2006 due to safety findings. Cholesterol levels will be measured over six weeks in subjects being treated with two different kinds of cholesterol medications to see how the…
- Conditions
- Hyperlipidemia, Dyslipidemia, Hypercholesterolemia
- Trial name
- NCT00267280
- Testing
- torcetrapib/atorvastatin, simvastatin
- Where
- 51 sites in United States
- Volunteers
- 640 people
- Sponsor
- Pfizer
Hypercholesterolemia
Centralized Pan-Middle East Survey on the Undertreatment of Hypercholesterolemia
The purpose of the study is to establish the proportion of patients on lipid-lowering pharmacological treatment reaching the LDL-C goals according to the NCEP ATP III/updated 2004 NCEP ATP III guidelines, overall and by country…
- Trial name
- CEPHEUS (NCT01025388)
- Where
- 5 sites in Saudi Arabia
- Volunteers
- 4,053 people
- Sponsor
- AstraZeneca
Hypertriglyceridemia
Efficacy of MND-2119 in Participants With Hypertriglyceridemia
The purpose of this study is to evaluate the efficacy and safety of MND-2119 compared to EPADEL CAPSULES 300 in participants with hypertriglyceridemia.
- Trial name
- NCT03693131
- Testing
- Icosapent (MND-2119), Icosapent (EPADEL CAPSULES 300)
- Where
- Japan
- Volunteers
- 580 people
- Sponsor
- Mochida Pharmaceutical Company, Ltd.
Hypercholesterolemia
Pharmacokinetics of Butyrate Tablet BKR-017
The purpose of this study is to evaluate the pharmacokinetic profile and systemic exposure of BKR-017 in individuals on statin therapy after a single dose and at steady state after seven days repeated twice daily dosing.
- Trial name
- NCT06556745
- Testing
- BKR-017
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- BioKier Inc.
Hyperlipidemia
Evaluation of ARI-3037MO, to Suppress LDL Cholesterol in Patients With Dyslipidemia
The objective of this study is to evaluate the efficacy and safety of ARI-3037MO compared to placebo in reducing low-density lipoprotein cholesterol (LDL-C) levels in subjects with dyslipidemia.
- Trial name
- REASCEND (NCT02532218)
- Testing
- ARI-3037MO
- Where
- 19 sites in United States
- Volunteers
- 176 people
- Sponsor
- Arisaph Pharmaceuticals Inc
Hypercholesterolaemia
Chart Review of Repatha® in Subjects With Hyperlipidaemia
Review of clinical characteristics of patients who are prescribed Repatha® and how their treatment is managed.
- Trial name
- HEYMANS (NCT02770131)
- Where
- 183 sites in Austria, Belgium and 10 more
- Volunteers
- 1,986 people
- Sponsor
- Amgen
Dyslipidemia
Retrospective Survey Evaluating the Effectiveness and Safety of Dual Inhibition Lipid-lowering in the Treatment of Dyslipidemia (Study P05171)(COMPLETED)
This retrospective study evaluates the effectiveness and safety of ezetimibe plus statin or ezetimibe plus fenofibrate in dyslipidemic patients that were treated with these dual inhibition lipid lowering regimens as part of their…
- Trial name
- NCT00726856
- Testing
- Ezetimibe 10 mg plus statin or ezetimibe 10 mg plus fenofibrate
- Volunteers
- 1,200 people
- Sponsor
- Organon and Co
Homozygous Familial Hypercholesterolemia
Effects of Lomitapide on Carotid and Aortic Atherosclerosis
Study to assess changes in carotid and aortic atherosclerosis in patients being treated with lomitapide.
- Trial name
- NCT02399852
- Testing
- Lomitapide
- Sponsor
- Aegerion Pharmaceuticals, Inc.
Dyslipidaemia
A Study to Investigate the Effect of AZD0780 Tablets in Combination With Rosuvastatin Tablets on Low Density Lipoprotein Cholesterol Levels (LDL-C) in Adult Participants With Dyslipidaemia
This is a study to investigate the effect of AZD0780 tablets on low density lipoprotein cholesterol levels (LDL-C) compared with placebo tablets administered in combination with rosuvastatin tablets in adult Russian participants…
- Trial name
- LAZURE (NCT07218900)
- Testing
- AZD0780, Rosuvastatin
- Where
- 8 sites in Russia
- Volunteers
- 76 people
- Sponsor
- AstraZeneca
Hyperlipidemia
Comparison of the Combination of Fenofibrate and Simvastatin Versus Pravastatin
Mixed or combined hyperlipidemia is a common metabolic disorder characterized by both hypercholesterolemia and hypertriglyceridemia.
- Trial name
- NCT00362206
- Testing
- Fenofibrate/Simvastatin, Pravastatin
- Where
- 41 sites in Greece, Israel and 3 more
- Volunteers
- 423 people
- Sponsor
- Solvay Pharmaceuticals
Dyslipidemias, Hypercholesterolemia
Effect of Statins on Lipid Levels Following the First Acute Coronary Event (MK-0000-204)
The current study is proposed to investigate the pattern of dyslipidemia and of lipid treatment practices in patients in India experiencing their first acute cardiovascular event and the extent of residual dyslipidemia after 12…
- Conditions
- Dyslipidemias, Hypercholesterolemia, Hypertriglyceridemia, High LDL-C
- Trial name
- REMAINS (NCT01245738)
- Volunteers
- 635 people
- Sponsor
- Merck Sharp & Dohme LLC
Hyperlipidemia
Efficacy and Safety Study of Lipid-Lowering Effects of XueZhiKang (XZK) in Patients With Hyperlipidemia
The purpose of this study is to demonstrate the efficacy of XueZhiKang to improve plasma lipid profile, as compared to placebo, in outpatients with hyperlipidemia.
- Trial name
- NCT01327014
- Testing
- XueZhiKang (XZK), a botanic product with multiple components
- Where
- 13 sites in United States, China
- Volunteers
- 116 people
- Sponsor
- Beijing Peking University WBL Biotech Co., Ltd.
Hypercholesterolemia and Hyperlipidemia
Study of Bioavailability, Pharmacodynamics and Safety of SHR-1209 Administered by Single Subcutaneous Injection at Different Sites in Healthy Volunteers
In order to meet the preferences and needs of different patients for injection sites and improve the medication compliance of patients, it is planned to compare the bioavailability, pharmacokinetics, pharmacodynamic and safety…
- Trial name
- NCT05370950
- Testing
- SHR-1209
- Where
- China
- Volunteers
- 159 people, healthy volunteers welcome
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
Hyperlipidemia and Mixed Dyslipidemia
Open-label Extension Study of Evolocumab (AMG 145) in Adults With Hyperlipidemia and Mixed Dyslipidemia
This study will contribute to the evaluation of long-term safety, tolerability and efficacy of evolocumab (AMG 145) in adults with hyperlipidemia and adults with mixed dyslipidemia.
- Trial name
- OSLER-2 (NCT01854918)
- Testing
- Evolocumab, Standard of Care
- Where
- 363 sites in United States, Australia and 23 more
- Volunteers
- 3,681 people
- Sponsor
- Amgen
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.